Valentis Licenses Geneswitch Technology To Wyeth-Ayers

Valentis, Inc. has granted a non-exclusive license of the Company’s GeneSwitch gene regulation technology to Wyeth-Ayerst Laboratories.

The GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, aiding in the identification and characterization of a gene’s function.

Valentis is currently developing the GeneSwitch system as a component of a regulated erythropoietin gene medicine that it expects to take into human clinical testing.

The non-exclusive license is for research purposes only and consists of an up-front payment and annual maintenance fees.

No financial terms were disclosed.

Valentis maintains all rights to clinical gene therapy applications of the GeneSwitch technology.

“GeneSwitch technology will enable and enhance our efforts to mine the human genome for novel drug discovery targets,” states Dr. Charles W. Richard, Assistant Vice President of Genomics for Wyeth- Ayerst Research, the research unit of Wyeth-Ayerst.

“In deciding to license the GeneSwitch technology to pharmaceutical companies, Valentis has identified another business opportunity for its broad technology portfolio,” stated Michael P. Fons, Valentis’ Director of Business Development.

“The GeneSwitch system was initially made available to the academic research community through a license to Invitrogen. The license to Wyeth Ayerst represents the first commercial license of this technology to a major pharmaceutical company. We expect to conclude a number of similar licenses over the next year.”

Valentis, Inc. is a leader in the field of biopharmaceutical delivery.

The Company develops a broad array of products, proprietary technologies and intellectual property and applies its preclinical and early clinical development expertise to create novel therapeutics and improved versions of existing marketed biopharmaceuticals.

Obtain Dragon Pharma LLC Legally

Winstrol Tabs

Synthetic Anabolic Steroidal Agent
Active Constituent: Stanozolol
Made by: Dragon Pharma Labs
Unit: 1 X 100 tabs (50 mg/tablet)

Winstrol Tabs - Cheap Price

Administration: Oral
Base Chemical Name: Stanozolol
Manufacturer: Dragon Pharma
Unit: 20 x 100 pastilles (50 mg/pastille)
Price: 20 x $58.00

Cut Long 300

Injectable Anabolic Steroid
Principal Chemical Name: Drostanolone Enanthate, Testosterone Enanthate, Trenbolone Enanthate
Produced by: Dragon Pharmaceutical
Pack: 1 X 10 ml (300 mg/ml)

Turanabol - Discount Price

Administration: Oral
Principal Chemical Name: Chlorodehydromethyltestosterone
Branded by: Dragon Pharmaceutical
Amount: 30 x 100 pastilles (10 mg/pill)
Price: 30 x $55.00

Clenbuterol - Bulk Price

Administration: Oral
Basal Constituent: Clenbuterol Hydrochloride
Made by: Dragon Pharmaceutical
Amount: 10 x 100 pastilles (40 mcg/pill)
Price: 10 x $25.00

Sustanon 350 - Cheap Price

Administration: Injection
Primary Chemical Name: Testosterone Blend
Producer: Dragon Pharma LLC
Unit: 20 x 10 mL vial (350 mg/mL)
Price: 20 x $40.00

Primobolan 100 - Discount Price

Administration: Injection
Active Ingredient: Methenolone Enanthate
Branded by: Dragon Pharmaceuticals
Pack: 30 x 10 mL vial (100 mg/mL)
Price: 30 x $55.00

NPP 150

Injectable Anabolic Steroid
Base Ingredient: Nandrolone Phenylpropionate
Branded by: Dragon Pharma LLC
Pack: 1 X 10 ml (150 mg/ml)

Masteron 200 - Bulk Price

Administration: Injection
Main Substance: Drostanolone Enanthate
Produced by: Dragon Pharmaceutical
Unit: 10 x 10 mL vial (200 mg/mL)
Price: 10 x $67.00

Dianabol 20 - Bulk Price

Administration: Oral
Base Substance: Methandrostenolone
Made by: Dragon Pharma Labs
Package: 10 x 100 pills (20 mg/pastille)
Price: 10 x $39.00


Principal Constituent: Clomiphene Citrate
Branded by: Dragon Pharma LLC
Unit: 100 pastilles (50 mg/pastille)


Oral Steroid for Muscle Growth
Main Chemical Name: Chlorodehydromethyltestosterone
Branded by: Dragon Pharma LLC
100 pills (20 mg/tab)